News >

Vaccine Shows Signs of Stimulatory Effects in Early-Stage CRC

Caroline Seymour
Published: Wednesday, May 08, 2019

Karen E. Knudsen, PhD

Karen E. Knudsen, PhD

A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer (CRC), induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population, according to results of a first-in-human phase I trial (NCT01972737).1,2

“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” Snook said in the press release.

References

  1. Snook A, Baybutt T, Xiang B, et al. Split tolerance permits safe AD5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Can. 2019;7(104). doi: 10.1186/s40425-019-0576-2.
  2. Novel Vaccine for Colorectal Cancer Shows Positive Phase I Results. Jefferson Health. Published April 29, 2019. https://bit.ly/2PLjDvo. Accessed April 30, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x